- Home
- CENN vs BTAI Comparison
CENN vs BTAI Comparison
Compare CENN & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CENN
- BTAI
- Stock Information
- Founded
- CENN 2013
- BTAI 2017
- Country
- CENN United States
- BTAI United States
- Employees
- CENN N/A
- BTAI N/A
- Industry
- CENN Auto Manufacturing
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- CENN Consumer Discretionary
- BTAI Health Care
- Exchange
- CENN Nasdaq
- BTAI Nasdaq
- Market Cap
- CENN 35.8M
- BTAI 28.7M
- IPO Year
- CENN N/A
- BTAI 2018
- Fundamental
- Price
- CENN $1.02
- BTAI $0.36
- Analyst Decision
- CENN
- BTAI Strong Buy
- Analyst Count
- CENN 0
- BTAI 4
- Target Price
- CENN N/A
- BTAI $5.00
- AVG Volume (30 Days)
- CENN 130.1K
- BTAI 949.6K
- Earning Date
- CENN 02-12-2025
- BTAI 11-14-2024
- Dividend Yield
- CENN N/A
- BTAI N/A
- EPS Growth
- CENN N/A
- BTAI N/A
- EPS
- CENN N/A
- BTAI N/A
- Revenue
- CENN $37,052,841.00
- BTAI $2,276,000.00
- Revenue This Year
- CENN N/A
- BTAI $164.86
- Revenue Next Year
- CENN N/A
- BTAI $69.74
- P/E Ratio
- CENN N/A
- BTAI N/A
- Revenue Growth
- CENN 142.48
- BTAI 83.25
- 52 Week Low
- CENN $1.00
- BTAI $0.35
- 52 Week High
- CENN $2.30
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- CENN 28.64
- BTAI 32.49
- Support Level
- CENN $1.17
- BTAI $0.35
- Resistance Level
- CENN $1.19
- BTAI $0.52
- Average True Range (ATR)
- CENN 0.06
- BTAI 0.06
- MACD
- CENN -0.02
- BTAI -0.00
- Stochastic Oscillator
- CENN 0.00
- BTAI 2.92
About CENN Cenntro Electric Group Limited
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles. Its vehicles include Metro, Logistar 400, Logistar 200, Neibor 200, and ORV. The company's geographical segments include Europe, America, and Asia.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.